Yes. A number of large randomized controlled trials have shown inhaled corticosteroids to be beneficial in low doses for patients who have mild persistent asthma, and therefore these drugs are strongly recom mended in this situation. 1 Asthma care providers should, however, consider this "yes" in the context of asthma severity, the goals of therapy, and the benefits and risks associated with inhaled cortico steroids.
■ CLASSIFICATION OF ASTHMA SEVERITY
The third Expert Panel Report (EPR3) categorizes asthma as intermittent (for merly called "mild intermittent"), mild persistent, moderate persistent, or severe persistent (TABLE 1) . 1 Although the studies of asthma prevalence had methodologic limitations and therefore the true prevalence of mild persistent asthma cannot be determined, it is common. Fuhl brigge et al 2 reported that most asthma pa tients have some form of persistent asthma. In contrast, Dusser et al 3 reviewed available studies and concluded that most patients with asthma have either intermittent or mild per sistent asthma.
■ GOALS: REDUCE IMPAIRMENT AND RISK
The goals of asthma management are to:
Reduce impairment by controlling symp toms so that normal activity levels can be maintained, by minimizing the need for short acting bronchodilator use, and by maintain ing normal pulmonary function; and to Reduce risk by preventing progressive loss of lung function and recurrent exacerbations, and by optimizing pharmacotherapy while minimizing potential adverse effects. 1 
■ EVIDENCE OF BENEFIT
The benefits of inhaled corticosteroids in mild persistent asthma were established by a number of large prospective clinical trials (TABLE 2) . [4] [5] [6] [7] [8] The OPTIMA trial 4 (Low Dose Inhaled Budesonide and Formoterol in Mild Persistent Asthma) was a doubleblind, randomized trial carried out in 198 centers in 17 countries. Com pared with those randomized to receive placebo, patients who were randomized to receive an in haled corticosteroid, ie, budesonide (Pulmicort) 100 μg twice daily, had 60% fewer severe exacer bations (relative risk [RR] 0.4, 95% confidence interval [CI] 0.27-0.59) and 48% fewer days when their asthma was poorly controlled (RR 0.52, 95% CI 0.4-0.67). Adding a longacting betaagonist did not change this outcome.
The START study 5 (Inhaled Steroid Treatment as Regular Therapy in Early Asth ma) showed that, compared with placebo, starting inhaled budesonide within the first 2 years of asthma symptoms in patients with mild persistent asthma was associated with better asthma control and less need for addi tional asthma medication.
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Despite this strong evidence supporting regular use of inhaled corticosteroids in pa tients with mild persistent asthma, many pa tients choose to take them intermittently.
Suissa et al 7 found, in a large observational cohort study, that fewer patients died of asth ma if they were receiving lowdose inhaled corticosteroids than if they were not. The rate of death due to asthma was lower in patients who had used more inhaled corticosteroids over the previous year, and the death rate was higher in those who had discontinued inhaled corticosteroids in the previous 3 months than in those who continued using them.
■ STEROIDS DO NOT SLOW THE LOSS OF LUNG FUNCTION
Compared with people without asthma, asthma patients have substantially lower values of forced expiratory volume in the first second of expira tion (FEV 1 ). They also have a faster rate of func tional decline: the average decrease in FEV 1 in asthma patients is 38 mL per year, compared with 22 mL per year in nonasthmatic people. 9 Although inhaled corticosteroids have been shown to increase lung function in asth ma patients in the short term, there is little convincing evidence to suggest that they affect the rate of decline in the long term. 10 In fact, airway inflammation and bronchial hyperre sponsiveness return to baseline within 2 weeks after inhaled corticosteroids are discontinued. 10 
■ DO INHALED CORTICOSTEROIDS STUNT CHILDREN'S GROWTH?
The safety of longterm lowdose inhaled corticosteroids is well established in adults. However, two large randomized controlled tri als found that children treated with lowdose inhaled steroids (budesonide 200-400 μg per day) grew 1 to 1.5 cm less over 3 to 5 years of treatment than children receiving placebo.
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However, this effect was primarily evident within the first year of therapy, and growth ve locity was similar to that with placebo at the end of the treatment period (4 to 6 years). 12 Agertoft and Pedersen 13 found that taking inhaled corticosteroids longterm is unlikely to have an effect on final height. Children who took inhaled budesonide (up to an aver age daily dose of 500 μg) into adulthood ended up no shorter than those who did not.
Based on these and other data, inhaled corticosteroids are generally considered safe at recommended doses. However, the decision to prescribe them for longterm therapy should be based on the risks and benefits to the indi vidual patient. Significantly lower risk of a severe asthma-related event with budesonide 400 μg (200 μg for those under age 11 years) vs placebo (odds ratio 0.61, P < .001)
IMPACT 6
Compared with intermittent budesonide or continued zafirlukast (Accolate) use, continuous budesonide use (200 μg twice daily) resulted in greatest improvement in prebronchodilator FEV 1 (P < .005), bronchial reactivity (P < .001), sputum eosinophils (P < .006), exhaled nitric oxide (P < .007), and symptom-free days (P < .03)
Zafirlukast 20 mg twice daily was similar to intermittent budesonide for all outcomes measured 
■ ALTERNATIVE DRUGS FOR MILD PERSISTENT ASTHMA
Leukotrienemodifying drugs include the leuko triene receptor antagonists montelukast (Singulair) and zafirlukast and the 5lipoxy genase inhibitor zileuton (Zyflo CR). These drugs have been associated with statistically significant improvement in FEV 1 compared with placebo in patients with mild to moder ate asthma, reductions in both blood and spu tum eosinophils, 14 and attenuation of bron choconstriction with exercise.
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Large randomized trials comparing leuko triene modifier therapy with lowdose inhaled steroids in adults and children with mild persistent asthma have found that although outcomes improve with either therapy, the improvement is statistically superior with in haled steroids for most asthmacontrol mea sures. 6, 8 Lowdose inhaled steroid therapy in patients with mild persistent and moderate persistent asthma has been associated with su perior clinical outcomes as well as greater im provement in pulmonary function than treat ment with antileukotriene drugs (TABLE 2). 8 Asthma is heterogeneous, and properly selected patients with mild persistent asthma may achieve good control with leukotriene modifier monotherapy. 15 Alternatives for pa tients with mild persistent asthma include the methylxanthine theophylline, but this drug is less desirable due to its narrow therapeutic in dex. 1 The inhaled cromones nedocromil (Ti lade) and cromolyn (Intal) were other options in this patient population, but their short half lives made them less practical, and US pro duction has been discontinued.
■ THE BOTTOM LINE
Inhaled corticosteroids are the most effective drug class for controlling mild persistent asthma and are generally regarded as safe for longterm Outcomes are better with daily than with as-needed inhaled corticosteroid therapy Though leukotriene receptor antagonists can be effec tive, the daily use of inhaled corticosteroids results in high er asthma control test scores, more symptomfree days, greater prebronchodilator FEV 1 , and decreased percent age of sputum eosinophils 6 in patients with mild persistent asthma, and the addition of a longacting beta agonist does not provide additional benefit. 4 Furthermore, daily use of inhaled corticosteroids in these patients has also been as sociated with a lower rate of asthmarelated deaths and with less need for systemic corticosteroid therapy, 7, 8 even though inhaled corticosteroids have not yet been shown to alter the progressive loss of lung function.
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